[1] DESANTIS CE, MA J, GAUDET MM, et al. Breast cancer statistics, 2019[J]. CA, 2019, 69(6): 438.
[2] 何明艳. 乳腺癌流行趋势分析与术后放疗效应研究[D]. 衡阳: 南华大学, 2019.
[3] SIEMENS H, JACKSTADT R, KALLER M, et al. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness[J]. Oncotarget, 2016, 4(9): 1399.
[4] LEE RC, FEINBAUM RL, AMBROS V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 2015, 75(5): 843.
[5] LEWIS BP, BURGE CB, BARTEL DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets[J]. Cell, 2015, 120(1): 15.
[6] MISSO G, DI MARTINO MT, DE ROSA G, et al. Mir-34: a new weapon against cancer?[J]. Mol Ther Nucleic Acids, 2014, 3(9): 194.
[7] ZENG L, FEE BE, RIVAS MV, et al. Adherens junctional associated protein-1: a novel 1p36 tumor suppressor candidate in gliomas (Review)[J]. Int J Oncol, 2014, 45(1): 13. doi: 10.3892/ijo.2014.2425
[8] CAMPOS-PARRA AD, MITZNAHUATL GC, PEDROZA-TORRES A, et al. Micro-RNAs as potential predictors of response to breast cancer systemic therapy: future clinical implications[J]. Int J Mol Sci, 2017, 18(6): 1182. doi: 10.3390/ijms18061182
[9] SHIMADA S, AKIYAMA Y, MOGUSHI K, et al. Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models[J]. Br J Cancer, 2018, 118(7): 972. doi: 10.1038/s41416-018-0008-y
[10] ROKAVEC M, LI H, JIANG L, et al. The p53/miR-34 axis in development and disease[J]. J Mol Cell Biol, 2015, 6(3): 214.
[11] HERMEKING H. The miR-34 family in cancer and apoptosis[J]. Cell Death Differ, 2016, 17(2): 193.